Literature DB >> 17486453

Aromatase inhibitors for breast cancer.

Susanne Briest1, Nancy E Davidson.   

Abstract

Endocrine therapy is a mainstay for the many women who develop in situ or invasive steroid receptor-positive breast cancer. The use of tamoxifen has reduced mortality in such women. Recently estrogen deprivation strategies have come under scrutiny. Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17486453     DOI： 10.1007/s11154-007-9039-z

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


  67 in total

1.  The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.

Authors:  Q Lu; Y Liu; B J Long; D Grigoryev; M Gimbel; A Brodie
Journal:  Breast Cancer Res Treat       Date:  1999-09       Impact factor: 4.872

2.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors:  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2006-07       Impact factor: 6.875

3.  Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

Authors:  Ian E Smith; Mitch Dowsett; Yoon-Sim Yap; Geraldine Walsh; Per E Lønning; Richard J Santen; Daniel Hayes
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

4.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

Authors:  M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; N Zilembo; J L Dugardyn; C Nasurdi; R G Mennel; J Cervek; C Fowst; A Polli; E di Salle; A Arkhipov; G Piscitelli; L L Miller; G Massimini
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

6.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

7.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

Authors:  A Buzdar; J Douma; N Davidson; R Elledge; M Morgan; R Smith; L Porter; J Nabholtz; X Xiang; C Brady
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

Review 8.  Mammographic breast density as an intermediate phenotype for breast cancer.

Authors:  Norman F Boyd; Johanna M Rommens; Kelly Vogt; Vivian Lee; John L Hopper; Martin J Yaffe; Andrew D Paterson
Journal:  Lancet Oncol       Date:  2005-10       Impact factor: 41.316

9.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors:  J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

10.  Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Authors:  D P Forward; K L Cheung; L Jackson; J F R Robertson
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640
View more
  5 in total

1.  Effect of nonmotorized wheel running on mammary carcinogenesis: circulating biomarkers, cellular processes, and molecular mechanisms in rats.

Authors:  Zongjian Zhu; Weiqin Jiang; Jennifer L Sells; Elizabeth S Neil; John N McGinley; Henry J Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

2.  Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.

Authors:  Keya De Mukhopadhyay; Zhao Liu; Abhik Bandyopadhyay; Nameer B Kirma; Rajeshwar R Tekmal; Shui Wang; Lu-Zhe Sun
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

3.  Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.

Authors:  Erik S Knudsen; Emily Schultz; Deanna Hamilton; Kris Attwood; Stephen Edge; Tracey O'Connor; Ellis Levine; Agnieszka K Witkiewicz
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

Review 4.  Benzofuran as a promising scaffold for the synthesis of antimicrobial and antibreast cancer agents: A review.

Authors:  Ghadamali Khodarahmi; Parvin Asadi; Farshid Hassanzadeh; Elham Khodarahmi
Journal:  J Res Med Sci       Date:  2015-11       Impact factor: 1.852

5.  New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.

Authors:  Yang Xi; Jiansheng Liu; Haiwei Wang; Shang Li; Yanghua Yi; Yanzhi Du
Journal:  Cancer Med       Date:  2020-10-01       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.